FREMONT, Calif., May 26, 2020 /PRNewswire/ -- Ardelyx, Inc.
(Nasdaq: ARDX), a specialized biopharmaceutical company focused on
developing innovative first-in-class medicines to improve treatment
for people with kidney and cardiovascular diseases, today announced
that Mike Raab, president and chief
executive officer of Ardelyx, will participate in a fireside chat
at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 3:00 p.m. ET.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 60 days
following the conference.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the way people with kidney and cardiovascular diseases are treated
by developing innovative first-in-class medicines. Ardelyx's
pipeline includes tenapanor for the control of serum phosphorus in
adult patients with CKD on dialysis, for which the Company is
preparing for NDA submission mid-year, and RDX013, a potassium
secretagogue program for the potential treatment of high potassium,
or hyperkalemia, a problem among certain patients with kidney
and/or heart disease. In addition, Ardelyx received FDA approval of
IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established
agreements with Kyowa Kirin Corporation in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and
commercialization of tenapanor in the respective territories.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2020-virtual-healthcare-conference-301064956.html
SOURCE Ardelyx